NQO1 Pro187Ser Polymorphism Confers to the Susceptibility of Prostate Cancer


Increasing epidemiological studies were recently performed to assess the relationship of NAD(P)H: quinine oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of prostate cancer (PCa) to yield inconsistent results. In this study, we aimed to generate large-scale evidence on whether NQO1 Pro187Ser polymorphism conferred to the susceptibility of PCa. The database of PubMed was comprehensively reviewed until September 12th, 2013, without any linguistic limitation. Meta-analysis was complied in the codominant, dominant, recessive and allele models by either fixed or random effect models. Odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to evaluate the strength of the association between the two. Finally, six eligible studies with 717 cases and 1764 controls were included. In overall analyses, significant associations were found in the dominant (OR = 1.26, 95%CI = 1.04 - 1.52, P = 0.02), allele (OR = 1.20, 95%CI = 1.03 - 1.40, P = 0.02) and the heterozygous codominant (OR = 1.24, 95%CI = 1.02 - 1.52, P = 0.03) models. Also, significant results were found in the stratified analyses by Hardy-Weinberg equilibrium (HWE). Still, subgroup analysis showed an increased risk of PCa in Asian rather than Caucasian population. Besides, NQO Pro187Ser polymorphism correlated with a heightened risk of PCa in the hospital-based studies. Our study indicated that NQO1 functional Pro187Ser polymorphism could be a potentially genetic biomarker for the risk of PCa, especially in Asian population.

Share and Cite:

Zhang, X. , Jiao, W. and Zhang, W. (2015) NQO1 Pro187Ser Polymorphism Confers to the Susceptibility of Prostate Cancer. Open Journal of Urology, 5, 238-245. doi: 10.4236/oju.2015.512038.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Ferlay, J., Parkin, D.M. and Steliarova-Foucher, E. (2010) Estimates of Cancer Incidence and Mortality in Europe in 2008. European Journal of Cancer, 46, 765-781.
[2] Jemal, A., Siegel, R., Xu, J. and Ward, E. (2010) Cancer Statistics, 2010. CA: A Cancer Journal for Clinicians, 60, 277-300.
[3] Bostwick, D.G., Burke, H.B., Djakiew, D., Euling, S., Ho, S.M., Landolph, J., Morrison, H., Sonawane, B., Shifflett, T., Waters, D.J. and Timms, B. (2004) Human Prostate Cancer Risk Factors. Cancer, 101, 2371-2490.
[4] Joseph, P. and Jaiswal, A.K. (1994) Nad(p)h:Quinone Oxidoreductase1 (dt Diaphorase) Specifically Prevents the Formation of Benzo[a]Pyrene Quinone-DNA Adducts Generated by Cytochrome p4501a1 and p450 Reductase. Proceedings of the National Academy of Sciences of the United States of America, 91, 8413-8417.
[5] Jaiswal, A.K., McBride, O.W., Adesnik, M. and Nebert, D.W. (1988) Human Dioxin-Inducible Cytosolic nad(p)h: Menadione Oxidoreductase. Cdna Sequence and Localization of Gene to Chromosome 16. Journal of Biological Chemistry, 263, 13572-13578.
[6] Traver, R.D., Siegel, D., Beall, H.D., Phillips, R.M., Gibson, N.W., Franklin, W.A. and Ross, D. (1997) Characterization of a Polymorphism in nad(p)h:Quinone Oxidoreductase (dt-Diaphorase). British Journal of Cancer, 75, 69-75.
[7] Steinbrecher, A., Rohrmann, S., Timofeeva, M., Risch, A., Jansen, E. and Linseisen, J. (2010) Dietary Glucosinolate Intake, Polymorphisms in Selected Biotransformation Enzymes, and Risk of Prostate Cancer. Cancer Epidemiology, Biomarkers & Prevention, 19, 135-143.
[8] Mandal, R.K., Nissar, K. and Mittal, R.D. (2012) Genetic Variants in Metabolizing Genes nqo1, nqo2, mthfr and Risk of Prostate Cancer: A Study from North India. Molecular Biology Reports, 39, 11145-11152.
[9] Stoehr, C.G., Nolte, E., Wach, S., Wieland, W.F., Hofstaedter, F., Hartmann, A. and Stoehr, R. (2012) Nad(p)h: Quinone Oxidoreductase 1 (nqo1) p187s Polymorphism and Prostate Cancer Risk in Caucasians. International Journal of Molecular Sciences, 13, 10959-10969.
[10] Ergen, H.A., Gormus, U., Narter, F., Zeybek, U., Bulgurcuoglu, S. and Isbir, T. (2007) Investigation of nad(p)h: Quinone Oxidoreductase 1 (nqo1) c609t Polymorphism in Prostate Cancer. Anticancer Research, 27, 4107-4110.
[11] Hamajima, N., Matsuo, K., Iwata, H., Shinoda, M., Yamamura, Y., Kato, T., Hatooka, S., Mitsudomi, T., Suyama, M., Kagami, Y., Ogura, M., Ando, M., Sugimura, Y. and Tajima, K. (2002) NAD(P)H:Quinone Oxidoreductase 1 (NQO1) C609T Polymorphism and the Risk of Eight Cancers for Japanese. International Journal of Clinical Oncology, 7, 103-108.
[12] Steiner, M., Hillenbrand, M., Borkowsi, M., Seiter, H. and Schuff-Werner, P. (1999) 606 C→T Polymorphism in NAD(P)H:Quinone Oxidoreductase Gene in Patients with Prostatic Adenocarcinoma or Benign Prostatic Hyperplasia. Cancer Letters, 135, 67-71.
[13] Mantel, N. and Haenszel, W. (1959) Statistical Aspects of the Analysis of Data from Retrospective Studies of Disease. Journal of the National Cancer Institute, 22, 719-748.
[14] Der Simonian, R. and Laird, N. (1986) Meta-Analysis in Clinical Trials. Controlled Clinical Trials, 7, 177-188.
[15] Asher, G., Lotem, J., Cohen, B., Sachs, L. and Shaul, Y. (2001) Regulation of p53 Stability and p53-Dependent Apoptosis by NADH Quinone Oxidoreductase 1. Proceedings of the National Academy of Sciences of the United States of America, 98, 1188-1193.
[16] Anwar, A., Dehn, D., Siegel, D., Kepa, J.K., Tang, L.J., Pietenpol, J.A. and Ross, D. (2003) Interaction of Human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) with the Tumor Suppressor Protein p53 in Cells and Cell-Free Systems. Journal of Biological Chemistry, 278, 10368-10373.
[17] Long, D.J., Waikel, R.L., Wang, X.J., Perlaky, L., Roop, D.R. and Jaiswal, A.K. (2000) NAD(P)H:Quinone Oxidoreductase 1 Deficiency Increases Susceptibility to Benzo(a)pyrene-Induced Mouse Skin Carcinogenesis. Cancer Research, 60, 5913-5915.
[18] Iskander, K., Gaikwad, A., Paquet, M., Long, D.J., Brayton, C., Barrios, R. and Jaiswal, A.K. (2005) Lower Induction of p53 and Decreased Apoptosis in NQO1-Null Mice Lead to Increased Sensitivity to Chemical-Induced Skin Carcinogenesis. Cancer Research, 65, 2054-2058.
[19] Siegel, D., Gustafson, D.L., Dehn, D.L., Han, J.Y., Boonchoong, P., Berliner, L.J. and Ross, D. (2004) NAD(P)H: Quinone Oxidoreductase 1: Role as a Superoxide Scavenger. Molecular Pharmacology, 65, 1238-1247.
[20] Dinkova-Kostova, A.T. and Talalay, P. (2010) NAD(P)H:Quinone Acceptor Oxidoreductase 1 (NQO1), a Multifunctional Antioxidant Enzyme and Exceptionally Versatile Cytoprotector. Archives of Biochemistry and Biophysics, 501, 116-123.
[21] Egger, M., Smith, G.D. and Phillips, A.N. (1997) Meta-Analysis: Principles and Procedures. BMJ, 315, 1533-1537.
[22] Li, D., Liu, J., Zhang, W., Ren, J., Yan, L., Liu, H. and Xu, Z. (2013) Association between HIF1A P582S and A588T Polymorphisms and the Risk of Urinary Cancers: A Meta-Analysis. PLoS ONE, 8, e63445.
[23] Li, D., Liu, H., Yan, L., Tang, Y., Ren, J. and Xu, Z. (2012) Lack of Association between Hogg1 Ser326Cys Polymorphism and the Risk of Bladder Cancer: A Meta-Analysis. Urologia Internationalis, 88, 88-94.
[24] Li, D., Tian, T., Guo, C., Ren, J., Yan, L., Liu, H. and Xu, Z. (2012) No Association of the MTHFR Gene A1298C Polymorphism with the Risk of Prostate Cancer: A Meta-Analysis. Experimental and Therapeutic Medicine, 3, 493-498.
[25] Liu, K., Tian, H., Yu, K.Z., Shen, W.Y., Mao, Z.C., Jin, C.H., Pan, H.B. and He, J.X. (2013) Association between NQO1 Pro187Ser Polymorphism and Esophageal Cancer: A Meta-Analysis. Tumor Biology, 35, 2063-2068.
[26] Zhao, H., Zhu, F., Sun, J. and Meng, X. (2013) Meta-Analysis of the Association between NQO1 Pro187Ser Polymorphism and Colorectal Cancer in Asians. Tumor Biology, 35, 2111-2116.
[27] Zhang, H., Wen, X. and Lu, X. (2013) Association between NAD(P)H:Quinone Oxidoreductase 1 rs1800566 Polymorphism and Risk of Bladder Cancer. Tumor Biology, 34, 3377-3381.
[28] Lajin, B. and Alachkar, A. (2013) The NQO1 Polymorphism C609T (Pro187Ser) and Cancer Susceptibility: A Comprehensive Meta-Analysis. British Journal of Cancer, 109, 1325-1337.
[29] Thakkinstian, A., McElduff, P., D’Este, C., Duffy, D. and Attia, J. (2005) A Method for Meta-Analysis of Molecular Association Studies. Statistics in Medicine, 24, 1291-1306.
[30] Eickelmann, P., Schulz, W.A., Rohde, D., Schmitz-Drager, B. and Sies, H. (1994) Loss of Heterozygosity at the NAD(P)H:Quinone Oxidoreductase Locus Associated with Increased Resistance against Mitomycin C in a Human Bladder Carcinoma Cell Line. Biological Chemistry Hoppe-Seyler, 375, 439-445.
[31] Siegel, D., Anwar, A., Winski, S.L., Kepa, J.K., Zolman, K.L. and Ross, D. (2001) Rapid Polyubiquitination and Proteasomal Degradation of a Mutant Form of NAD(P)H:Quinone Oxidoreductase 1. Molecular Pharmacology, 59, 263-268.
[32] Siegel, D., McGuinness, S.M., Winski, S.L. and Ross, D. (1999) Genotype-Phenotype Relationships in Studies of a Polymorphism in NAD(P)H:Quinone Oxidoreductase 1. Pharmacogenetics, 9, 113-121.
[33] Misra, V., Grondin, A., Klamut, H.J. and Rauth, A.M. (2000) Assessment of the Relationship between Genotypic Status of a DT-Diaphorase Point Mutation and Enzymatic Activity. British Journal of Cancer, 83, 998-1002.
[34] Hajos, A.K. and Winston, G.W. (1991) Purified NAD(P)H-Quinone Oxidoreductase Enhances the Mutagenicity of Dinitropyrenes in Vitro. Journal of Biochemical Toxicology, 6, 277-282.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.